Evaluation of the Use of Appetite Stimulants in Pediatric Patients with Cystic Fibrosis.

Autor: Kennedy K; From the Department of Pharmacy, Children's Health Children's Medical Center, Dallas, TX., Lee M; Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX., Sathe M; the Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX., Ueng CS; From the Department of Pharmacy, Children's Health Children's Medical Center, Dallas, TX., Sharma P; the Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX.
Jazyk: angličtina
Zdroj: Journal of pediatric gastroenterology and nutrition [J Pediatr Gastroenterol Nutr] 2023 Oct 01; Vol. 77 (4), pp. 565-572. Date of Electronic Publication: 2023 Jul 12.
DOI: 10.1097/MPG.0000000000003886
Abstrakt: Objective: Poor nutrition in patients with cystic fibrosis (CF) has been associated with lower lung function and increased morbidity and mortality. Conversely, better nutritional status has been associated with improved pulmonary function and fewer CF-associated complications. There is no consensus regarding appetite stimulant therapy in patients with CF (pwCF). The primary objective of this study was to determine if the use of appetite stimulants was associated with weight changes in pediatric pwCF in the ambulatory care setting.
Methods: This was a retrospective study that evaluated 62 pediatric pwCF who received cyproheptadine or mirtazapine for appetite stimulation for at least 6 consecutive months. Weight z scores were collected for each patient at baseline, 3, 6, and 12 months of therapy, if available.
Results: Increase in weight z score after 3 months of therapy was statistically significant based on both univariable and multivariable models when evaluating the entire cohort. The adjusted mean difference for change in weight z score was 0.33 ( P < 0.001) from baseline to month 3. There was a statistically significant improvement in pulmonary function after 3 and 6 months of therapy.
Conclusions: Appetite stimulant therapy was associated with improvement in weight z score in the first 3 months of treatment. Appetite stimulant therapy was associated with improvement in pulmonary function in the first 3 months of therapy, which supports the relationship between weight gain and improved pulmonary function in pwCF. These findings suggest that appetite stimulants contribute to weight gain in pediatric pwCF, particularly within the first 3 months of therapy.
Competing Interests: The authors report no conflicts of interest.
(Copyright © 2023 by European Society for European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.)
Databáze: MEDLINE
Externí odkaz: